Annual CFF
$3.43 M
-$36.04 M-91.32%
31 December 2023
Summary:
Sunshine Biopharma annual cash flow from financing activities is currently $3.43 million, with the most recent change of -$36.04 million (-91.32%) on 31 December 2023. During the last 3 years, it has risen by +$1.82 million (+113.00%). SBFMW annual CFF is now -91.32% below its all-time high of $39.47 million, reached on 31 December 2022.SBFMW Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$1.87 M
+$1.89 M+6628.19%
30 September 2024
Summary:
Sunshine Biopharma quarterly cash flow from financing activities is currently $1.87 million, with the most recent change of +$1.89 million (+6628.19%) on 30 September 2024. Over the past year, it has increased by +$1.93 million (+3035.46%). SBFMW quarterly CFF is now -93.59% below its all-time high of $29.12 million, reached on 30 June 2022.SBFMW Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$7.20 M
+$1.93 M+36.58%
30 September 2024
Summary:
Sunshine Biopharma TTM cash flow from financing activities is currently $7.20 million, with the most recent change of +$1.93 million (+36.58%) on 30 September 2024. Over the past year, it has increased by +$5.85 million (+429.84%). SBFMW TTM CFF is now -83.17% below its all-time high of $42.81 million, reached on 30 June 2022.SBFMW TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SBFMW Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -91.3% | +3035.5% | +429.8% |
| 3 y3 years | +113.0% | +46.3% | +87.0% |
| 5 y5 years | +549.2% | +1306.4% | +1272.7% |
SBFMW Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -91.3% | +113.0% | -93.6% | +189.0% | -83.2% | +429.8% |
| 5 y | 5 years | -91.3% | +674.6% | -93.6% | +189.0% | -83.2% | +3065.7% |
| alltime | all time | -91.3% | >+9999.0% | -93.6% | +189.0% | -83.2% |
Sunshine Biopharma Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $1.87 M(-6628.2%) | $7.20 M(+36.6%) |
| June 2024 | - | -$28.58 K(-100.5%) | $5.28 M(-43.7%) |
| Mar 2024 | - | $5.40 M(<-9900.0%) | $9.36 M(+173.3%) |
| Dec 2023 | $3.43 M(-91.3%) | -$30.52 K(-52.0%) | $3.43 M(+151.9%) |
| Sept 2023 | - | -$63.57 K(-101.6%) | $1.36 M(-4.5%) |
| June 2023 | - | $4.06 M(-853.9%) | $1.42 M(-94.6%) |
| Mar 2023 | - | -$538.30 K(-74.3%) | $26.49 M(-32.9%) |
| Dec 2022 | $39.47 M(+1258.7%) | -$2.10 M(<-9900.0%) | $39.47 M(-5.0%) |
| Sept 2022 | - | $0.00(-100.0%) | $41.54 M(-3.0%) |
| June 2022 | - | $29.12 M(+134.2%) | $42.81 M(+200.6%) |
| Mar 2022 | - | $12.44 M(<-9900.0%) | $14.24 M(+390.3%) |
| Dec 2021 | $2.90 M(+80.6%) | -$23.66 K(-101.9%) | $2.90 M(-24.6%) |
| Sept 2021 | - | $1.28 M(+131.7%) | $3.85 M(+24.2%) |
| June 2021 | - | $550.65 K(-50.0%) | $3.10 M(+14.5%) |
| Mar 2021 | - | $1.10 M(+19.2%) | $2.71 M(+68.5%) |
| Dec 2020 | $1.61 M(+263.6%) | $924.61 K(+76.2%) | $1.61 M(+107.8%) |
| Sept 2020 | - | $524.64 K(+229.9%) | $773.80 K(+102.7%) |
| June 2020 | - | $159.01 K(>+9900.0%) | $381.83 K(+67.8%) |
| Mar 2020 | - | $0.00(-100.0%) | $227.60 K(-48.5%) |
| Dec 2019 | $442.25 K(-16.2%) | $90.16 K(-32.0%) | $442.25 K(-15.7%) |
| Sept 2019 | - | $132.67 K(+2680.2%) | $524.89 K(+5.6%) |
| June 2019 | - | $4772.00(-97.8%) | $497.09 K(+0.7%) |
| Mar 2019 | - | $214.66 K(+24.2%) | $493.74 K(-6.4%) |
| Dec 2018 | $527.64 K(-21.3%) | $172.79 K(+64.8%) | $527.64 K(-7.3%) |
| Sept 2018 | - | $104.88 K(+7280.6%) | $569.02 K(-11.8%) |
| June 2018 | - | $1421.00(-99.4%) | $645.01 K(-24.4%) |
| Mar 2018 | - | $248.55 K(+16.1%) | $853.04 K(+27.2%) |
| Dec 2017 | $670.71 K(+106.6%) | $214.16 K(+18.4%) | $670.71 K(+27.5%) |
| Sept 2017 | - | $180.88 K(-13.6%) | $525.87 K(+47.7%) |
| June 2017 | - | $209.45 K(+216.3%) | $356.16 K(+57.1%) |
| Mar 2017 | - | $66.22 K(-4.5%) | $226.71 K(-30.2%) |
| Dec 2016 | $324.62 K | $69.33 K(+520.9%) | $324.62 K(-71.7%) |
| Sept 2016 | - | $11.16 K(-86.0%) | $1.15 M(-5.2%) |
| June 2016 | - | $80.00 K(-51.3%) | $1.21 M(-16.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2016 | - | $164.13 K(-81.6%) | $1.44 M(+3.3%) |
| Dec 2015 | $1.40 M(+114.9%) | $893.09 K(+1109.5%) | $1.40 M(+111.0%) |
| Sept 2015 | - | $73.84 K(-76.4%) | $662.81 K(-17.4%) |
| June 2015 | - | $313.42 K(+165.0%) | $802.47 K(+25.6%) |
| Mar 2015 | - | $118.28 K(-24.8%) | $639.05 K(-1.8%) |
| Dec 2014 | $650.78 K(+40.6%) | $157.28 K(-26.3%) | $650.78 K(+31.9%) |
| Sept 2014 | - | $213.50 K(+42.3%) | $493.50 K(+76.3%) |
| June 2014 | - | $150.00 K(+15.4%) | $280.00 K(+115.4%) |
| Mar 2014 | - | $130.00 K(>+9900.0%) | $130.00 K(-71.9%) |
| Dec 2013 | $463.00 K(-0.4%) | $0.00(0.0%) | $463.00 K(-9.7%) |
| Sept 2013 | - | $0.00(0.0%) | $513.00 K(-40.7%) |
| June 2013 | - | $0.00(-100.0%) | $865.50 K(-5.5%) |
| Mar 2013 | - | $463.00 K(+826.0%) | $915.50 K(+96.9%) |
| Dec 2012 | $465.00 K(+137.7%) | $50.00 K(-85.8%) | $465.00 K(+12.0%) |
| Sept 2012 | - | $352.50 K(+605.0%) | $415.00 K(+60.8%) |
| June 2012 | - | $50.00 K(+300.0%) | $258.10 K(+24.0%) |
| Mar 2012 | - | $12.50 K(>+9900.0%) | $208.10 K(+6.4%) |
| Dec 2011 | $195.60 K(-50.9%) | $0.00(-100.0%) | $195.60 K(-60.4%) |
| Sept 2011 | - | $195.60 K(>+9900.0%) | $494.20 K(+24.0%) |
| June 2011 | - | $0.00(0.0%) | $398.60 K(0.0%) |
| Mar 2011 | - | $0.00(-100.0%) | $398.60 K(0.0%) |
| Dec 2010 | $398.60 K(+2244.7%) | $298.60 K(+198.6%) | $398.60 K(+298.6%) |
| Sept 2010 | - | $100.00 K(>+9900.0%) | $100.00 K(-84.6%) |
| June 2010 | - | $0.00(0.0%) | $649.00 K(-0.2%) |
| Mar 2010 | - | $0.00(-100.0%) | $650.50 K(-0.2%) |
| Oct 2009 | - | $649.00 K(>+9900.0%) | $652.00 K(>+9900.0%) |
| July 2009 | - | $1500.00(0.0%) | $6500.00(-45.8%) |
| Apr 2009 | - | $1500.00(>+9900.0%) | $12.00 K(+14.3%) |
| Jan 2009 | - | $0.00(-100.0%) | $10.50 K(0.0%) |
| Oct 2008 | - | $3500.00(-50.0%) | $10.50 K(+50.0%) |
| July 2008 | $17.00 K(-5.6%) | $7000.00(>+9900.0%) | $7000.00(>+9900.0%) |
| Apr 2008 | - | $0.00(0.0%) | $0.00(0.0%) |
| Jan 2008 | - | $0.00(0.0%) | $0.00(0.0%) |
| Oct 2007 | - | $0.00 | $0.00 |
| July 2007 | $18.02 K | - | - |
FAQ
- What is Sunshine Biopharma annual cash flow from financing activities?
- What is the all time high annual CFF for Sunshine Biopharma?
- What is Sunshine Biopharma annual CFF year-on-year change?
- What is Sunshine Biopharma quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Sunshine Biopharma?
- What is Sunshine Biopharma quarterly CFF year-on-year change?
- What is Sunshine Biopharma TTM cash flow from financing activities?
- What is the all time high TTM CFF for Sunshine Biopharma?
- What is Sunshine Biopharma TTM CFF year-on-year change?
What is Sunshine Biopharma annual cash flow from financing activities?
The current annual CFF of SBFMW is $3.43 M
What is the all time high annual CFF for Sunshine Biopharma?
Sunshine Biopharma all-time high annual cash flow from financing activities is $39.47 M
What is Sunshine Biopharma annual CFF year-on-year change?
Over the past year, SBFMW annual cash flow from financing activities has changed by -$36.04 M (-91.32%)
What is Sunshine Biopharma quarterly cash flow from financing activities?
The current quarterly CFF of SBFMW is $1.87 M
What is the all time high quarterly CFF for Sunshine Biopharma?
Sunshine Biopharma all-time high quarterly cash flow from financing activities is $29.12 M
What is Sunshine Biopharma quarterly CFF year-on-year change?
Over the past year, SBFMW quarterly cash flow from financing activities has changed by +$1.93 M (+3035.46%)
What is Sunshine Biopharma TTM cash flow from financing activities?
The current TTM CFF of SBFMW is $7.20 M
What is the all time high TTM CFF for Sunshine Biopharma?
Sunshine Biopharma all-time high TTM cash flow from financing activities is $42.81 M
What is Sunshine Biopharma TTM CFF year-on-year change?
Over the past year, SBFMW TTM cash flow from financing activities has changed by +$5.85 M (+429.84%)